Comparative Efficacy of Two Doses of Nebulized Colistimethate for the Eradication ofPseudomonas Aeruginosain Children with Cystic Fibrosis | Zendy

MarieSophie Brochet | Zendy; Anne-Catherine McDuff | Zendy; JeanFrançois Bussières | Zendy; E. Caron | Zendy; Geneviève Fortin | Zendy; Denis Lebel | Zendy; Jacques-Édouard Marcotte | Zendy

Open Access

Comparative Efficacy of Two Doses of Nebulized Colistimethate for the Eradication ofPseudomonas Aeruginosain Children with Cystic Fibrosis

Author(s) -

MarieSophie Brochet,

Anne-Catherine McDuff,

JeanFrançois Bussières,

E. Caron,

Geneviève Fortin,

Denis Lebel,

Jacques-Édouard Marcotte

Publication year - 2007

Publication title -

canadian respiratory journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.675

H-Index - 53

eISSN - 1916-7245

pISSN - 1198-2241

DOI - 10.1155/2007/673976

Subject(s) - medicine , cystic fibrosis , pseudomonas aeruginosa , prospective cohort study , retrospective cohort study , significant difference , genetics , bacteria , biology

Cystic fibrosis (CF) affects the respiratory and digestive systems. It evolves toward deterioration of pulmonary function through colonization with Pseudomonas aeruginosa. There is no consensus with respect to its eradication. Nebulized colistimethate is used for eradication treatment, but the optimal dose and duration is yet to be determined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research